Literature DB >> 7593231

Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.

E H Allan1, T J Martin.   

Abstract

The bone resorbing agent, prostaglandin E2 (PGE2), was found to alter several components of the plasminogen activator (PA)/plasmin pathway in primary cultures of rat neonatal osteoblast-like cells. The mRNA and activities of both urokinase-type PA (uPA) and tissue-type PA (tPA) were enhanced by PGE2 treatment. The presence of mRNA for the uPA receptor (uPAR) has been demonstrated in these cells and steady-state levels shown to be greatly enhanced, the response being rapid and sustained for at least 24 hours. mRNA for plasminogen activator inhibitor 1 (PAI-1) was modulated in a biphasic manner, with inhibition of the constitutive level apparent at 4 hours of treatment and stimulation apparent at 12 hours and longer, while PAI-1 protein, measured by an ELISA assay for rat PAI-1, was diminished over this period. Neither PAI-2 mRNA nor mRNA for the broad spectrum protease inhibitor, protease nexin-1 (PN-1), was found to be modulated by PGE2. Therefore, PGE2 is likely to stimulate cell surface proteolytic activity, since uPA mRNA and cell-associated activity were elevated, as was mRNA for the cellular receptor for uPA. Although it was not possible to measure uPAR number and affinity it seems likely that elevated uPAR mRNA would translate into increased uPARs which would localize the increased uPA activity to the pericellular region. tPA mRNA and activity were also increased transiently with the activity inhibited with prolonged incubations, apparently by PAI-1. Elevation of tPA mRNA and activity may result in elevated activity within the extracellular matrix as tPA has been reported to associate with several matrix proteins. Thus the early effect of PGE2 would be to promote proteolysis, both pericellularly and in the extracellular matrix. The inhibition of PAI-1 mRNA and protein, which would contribute to the elevation of activity, is due to PGE2, but the later stimulatory effect on PAI-1 mRNA may be due to feedback regulation by transforming growth factor beta (TGF beta), secreted by osteoblasts and activated by elevated levels of PA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593231     DOI: 10.1002/jcp.1041650310

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.

Authors:  Kristy A Bauman; Scott H Wettlaufer; Katsuhide Okunishi; Kevin M Vannella; Joshua S Stoolman; Steven K Huang; Anthony J Courey; Eric S White; Cory M Hogaboam; Richard H Simon; Galen B Toews; Thomas H Sisson; Bethany B Moore; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

Review 2.  Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?

Authors:  Steven K Huang; Marc Peters-Golden
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

3.  The Tissue Fibrinolytic System Contributes to the Induction of Macrophage Function and CCL3 during Bone Repair in Mice.

Authors:  Naoyuki Kawao; Yukinori Tamura; Yoshitaka Horiuchi; Katsumi Okumoto; Masato Yano; Kiyotaka Okada; Osamu Matsuo; Hiroshi Kaji
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

4.  Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.

Authors:  Khaled Shahrour; Rick Keck; Jerzy Jankun
Journal:  Biomed Res Int       Date:  2015-03-26       Impact factor: 3.411

5.  Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.

Authors:  Orla Cunningham; Suzanne Campion; V Hugh Perry; Carol Murray; Nicolai Sidenius; Fabian Docagne; Colm Cunningham
Journal:  Glia       Date:  2009-12       Impact factor: 7.452

6.  Berberine protects against esophageal mucosal damage in reflux esophagitis by suppressing proinflammatory cytokines.

Authors:  Byung Kil Choo; Seong-Soo Roh
Journal:  Exp Ther Med       Date:  2013-07-04       Impact factor: 2.447

Review 7.  Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways.

Authors:  Vidyani Suryadevara; Ramaswamy Ramchandran; David W Kamp; Viswanathan Natarajan
Journal:  Int J Mol Sci       Date:  2020-06-15       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.